Showing results 1 to 4 of 4
Title | Author(s) | Issue Date | |
---|---|---|---|
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection Journal:Journal of Hepatology | 2018 | ||
RETRACTION: Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection Journal:Clinical Gastroenterology and Hepatology | 2018 | ||
Review: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data Journal:Alimentary Pharmacology & Therapeutics | 2022 | ||
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial Journal:The Lancet Gastroenterology & Hepatology | 2016 |